UPB
Upstream Bio, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-54/100
Last price
4.59
▼ 0.26 (5.36%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.84
Prev close
4.85
Day high
4.87
Day low
4.53
Volume
1.06M
Market cap
$251.40M
P/E (TTM)
—
52W range
4.53 – 33.68
Day trading desk
Gap from prior close
-0.21%
Prior close 4.85
VWAP
4.61
-0.44% from price
Relative volume
3.16×
Unusually busy
Session range
8.11%
4.50 – 4.86
Position in range
25%
Near session low
ATR (14D)
0.30
6.48% of price
Prior day high
5.10
PDH
Prior day low
4.66
PDL
Bid / ask spread
—
Quote not published
Session volume
1.89M
Avg 598.57K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-11.56%
-13.5%
1M
-23.63%
-24.8%
3M
-42.48%
-47.0%
6M
-52.68%
-70.9%
YTD
-83.09%
-97.3%
1Y
-75.36%
-91.8%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on UPB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 16, 26 | GRAY MICHAEL P Chief Operating Officer |
SELL | 853 | $4.68K | Direct |
| Sep 16, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
SELL | 2.10K | $11.50K | Direct |
| Sep 16, 26 | HOUGHTON ADAM Officer |
SELL | 700 | $3.84K | Direct |
| Sep 16, 26 | DEYKIN AARON Officer |
SELL | 895 | $4.91K | Direct |
| Sep 16, 26 | AMBROSE ALLISON General Counsel |
SELL | 485 | $2.66K | Direct |
| Jun 16, 26 | GRAY MICHAEL P Chief Operating Officer |
SELL | 853 | $5.20K | Direct |
| Jun 16, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
SELL | 2.10K | $12.78K | Direct |
| Jun 16, 26 | HOUGHTON ADAM Officer |
SELL | 700 | $4.27K | Direct |
| Jun 16, 26 | DEYKIN AARON Officer |
SELL | 895 | $5.46K | Direct |
| Jun 16, 26 | AMBROSE ALLISON General Counsel |
SELL | 477 | $2.91K | Direct |
| Mar 16, 26 | GRAY MICHAEL P Chief Operating Officer |
SELL | 852 | $7.92K | Direct |
| Mar 16, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
SELL | 2.09K | $19.44K | Direct |
| Mar 16, 26 | HOUGHTON ADAM Officer |
SELL | 699 | $6.49K | Direct |
| Mar 16, 26 | DEYKIN AARON Officer |
SELL | 894 | $8.30K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AI UPSTREAM LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
AMBROSE ALLISON |
General Counsel | 15.56K | Sale |
CHIMOVITS EREZ |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
DEYKIN AARON |
Officer | 32.30K | Sale |
GRAY MICHAEL P |
Chief Operating Officer | 27.94K | Sale |
HOUGHTON ADAM |
Officer | 22.90K | Sale |
ORBIMED ADVISORS, L.L.C. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SUTHERLAND EVERETT RAND |
Chief Executive Officer | 68.72K | Sale |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II |
Beneficial Owner of more than 10% of a Class of Security | 894.73K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$251.40M
Enterprise value$-8.95M
Revenue (TTM)$3.16M
Gross profit$3.16M
EBITDA$-169.78M
Net income$-156.50M
EPS (TTM)$-2.73
Free cash flow$-86.62M
Total cash$261.31M
Total debt$954.00K
Book value / share$4.95
Shares outstanding54.77M
Float42.81M
Short % of float12.60%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.64
PEG ratio—
Price / sales—
Price / book0.93
EV / revenue-2.84
EV / EBITDA0.05
Gross margin100.00%
Operating margin-5480.98%
Profit margin0.00%
Return on equity-46.05%
Return on assets-30.28%
Debt / equity0.35
Current ratio27.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.85M | $2.37M | $2.38M | $1.21M | +20.4% |
| Operating revenue | $2.85M | $2.37M | $2.38M | $1.21M | +20.4% |
| Research & development | $136.81M | $62.97M | $31.80M | $18.66M | +117.3% |
| Selling, general & admin | $26.41M | $17.17M | $10.70M | $6.46M | +53.8% |
| Total operating expense | $163.22M | $80.13M | $42.49M | $25.12M | +103.7% |
| Operating income | -$160.36M | -$77.76M | -$40.11M | -$23.91M | -106.2% |
| Net interest income | $16.93M | $12.12M | $4.17M | $205.00K | +39.7% |
| Pre-tax income | -$143.44M | -$62.81M | -$20.54M | -$23.87M | -128.4% |
| Net income | -$143.44M | -$62.81M | -$20.54M | -$23.87M | -128.4% |
| Net income to common | -$143.44M | -$76.39M | -$38.26M | -$23.87M | -87.8% |
| Basic EPS | -2.64 | -1.17 | -1.05 | -0.66 | -125.7% |
| Diluted EPS | -2.64 | -1.17 | -1.05 | -0.66 | -125.7% |
| EBIT | -$160.36M | -$77.76M | -$40.11M | -$23.91M | -106.2% |
| EBITDA | -$160.17M | -$77.67M | -$40.05M | -$23.90M | -106.2% |
| Basic shares | 54.24M | 53.60M | 36.32M | 36.32M | +1.2% |
| Diluted shares | 54.24M | 53.60M | 36.32M | 36.32M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $101.58M | $325.89M | $25.83M | $17.05M | -68.8% |
| Cash & short-term investments | $341.51M | $470.45M | $109.81M | $17.05M | -27.4% |
| Accounts receivable | $668.00K | $613.00K | $98.00K | $412.00K | +9.0% |
| Total current assets | $351.80M | $479.16M | $117.00M | $18.31M | -26.6% |
| Property, plant & equipment | $1.78M | $2.37M | $202.00K | $164.00K | -24.7% |
| Total assets | $353.77M | $481.72M | $117.20M | $18.48M | -26.6% |
| Total current liabilities | $13.45M | $10.74M | $6.51M | $4.86M | +25.3% |
| Total debt | $1.27M | $1.83M | $45.00K | $94.00K | -30.8% |
| Total liabilities | $14.00M | $11.87M | $240.32M | $124.63M | +18.0% |
| Retained earnings | -$334.22M | -$190.78M | -$127.97M | -$107.44M | -75.2% |
| Shareholder equity | $339.77M | $469.85M | -$123.13M | -$106.16M | -27.7% |
| Working capital | $338.35M | $468.42M | $110.48M | $13.45M | -27.8% |
| Net tangible assets | $339.77M | $469.85M | -$123.13M | -$106.16M | -27.7% |
| Shares issued | 54.24M | 53.60M | 51.34M | 51.34M | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$143.44M | -$62.81M | -$20.54M | -$23.87M | -128.4% |
| Depreciation & amortisation | $188.00K | $89.00K | $60.00K | $7.00K | +111.2% |
| Stock-based compensation | $10.33M | $6.00M | $3.43M | $1.28M | +72.1% |
| Change in working capital | $589.00K | $1.87M | -$4.30M | $3.41M | -68.6% |
| Operating cash flow | -$133.28M | -$59.17M | -$37.93M | -$19.02M | -125.2% |
| Capital expenditure | -$165.00K | -$511.00K | -$144.00K | -$82.00K | +67.7% |
| Investing cash flow | -$93.48M | -$59.48M | -$82.84M | -$82.00K | -57.1% |
| Financing cash flow | $2.44M | $418.91M | $129.55M | $9.96M | -99.4% |
| Free cash flow | -$133.44M | -$59.68M | -$38.07M | -$19.10M | -123.6% |
| End cash position | $101.77M | $326.09M | $25.83M | $17.05M | -68.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $773.00K | $1.03M | $668.00K | $683.00K | $937.00K | -25.2% |
| Operating revenue | $773.00K | $1.03M | $668.00K | $683.00K | $937.00K | -25.2% |
| Research & development | $36.09M | $36.56M | $40.17M | $32.98M | $37.87M | -1.3% |
| Selling, general & admin | $7.05M | $8.08M | $6.67M | $5.54M | $7.42M | -12.8% |
| Total operating expense | $43.14M | $44.65M | $46.84M | $38.52M | $45.28M | -3.4% |
| Operating income | -$42.37M | -$43.62M | -$46.17M | -$37.83M | -$44.35M | +2.9% |
| Net interest income | $2.66M | $3.05M | $3.65M | $4.11M | $4.43M | -12.9% |
| Pre-tax income | -$39.70M | -$40.59M | -$42.46M | -$33.75M | -$39.97M | +2.2% |
| Net income | -$39.70M | -$40.59M | -$42.46M | -$33.75M | -$39.97M | +2.2% |
| Net income to common | -$39.70M | -$40.59M | -$42.46M | -$33.75M | -$39.97M | +2.2% |
| Basic EPS | -0.72 | -0.75 | -0.78 | -0.63 | -0.74 | +2.8% |
| Diluted EPS | -0.72 | -0.75 | -0.78 | -0.63 | -0.74 | +2.8% |
| EBIT | -$42.37M | -$43.62M | -$46.17M | -$37.83M | -$44.35M | +2.9% |
| EBITDA | -$42.32M | -$43.57M | -$46.11M | -$37.79M | -$44.30M | +2.9% |
| Basic shares | 54.77M | 54.42M | 54.24M | 53.93M | 53.80M | +0.6% |
| Diluted shares | 54.77M | 54.42M | 54.24M | 53.93M | 53.80M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.40M | $96.72M | $101.58M | $72.16M | $45.46M | -17.9% |
| Cash & short-term investments | $261.31M | $294.58M | $341.51M | $372.43M | $393.58M | -11.3% |
| Accounts receivable | $772.00K | $1.03M | $668.00K | $683.00K | $937.00K | -25.3% |
| Total current assets | $279.60M | $316.28M | $351.80M | $389.02M | $418.27M | -11.6% |
| Property, plant & equipment | $1.38M | $1.58M | $1.78M | $1.98M | $2.06M | -13.0% |
| Total assets | $281.17M | $318.05M | $353.77M | $391.19M | $420.52M | -11.6% |
| Total current liabilities | $9.99M | $13.67M | $13.45M | $11.91M | $10.93M | -26.9% |
| Total debt | $954.00K | $1.11M | $1.27M | $1.42M | $1.56M | -14.4% |
| Total liabilities | $10.21M | $14.06M | $14.00M | $12.61M | $11.78M | -27.3% |
| Retained earnings | -$414.52M | -$374.81M | -$334.22M | -$291.76M | -$258.02M | -10.6% |
| Shareholder equity | $270.96M | $304.00M | $339.77M | $378.58M | $408.74M | -10.9% |
| Working capital | $269.61M | $302.61M | $338.35M | $377.11M | $407.34M | -10.9% |
| Net tangible assets | $270.96M | $304.00M | $339.77M | $378.58M | $408.74M | -10.9% |
| Shares issued | 54.77M | 54.42M | 54.24M | 54.00M | 53.80M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$39.70M | -$40.59M | -$42.46M | -$33.75M | -$39.97M | +2.2% |
| Depreciation & amortisation | $50.00K | $49.00K | $57.00K | $46.00K | $42.00K | +2.0% |
| Stock-based compensation | $4.35M | $4.65M | $2.51M | $2.59M | $2.60M | -6.3% |
| Change in working capital | -$440.00K | -$11.35M | $7.75M | $8.88M | -$1.06M | +96.1% |
| Operating cash flow | -$35.62M | -$47.85M | -$30.63M | -$22.24M | -$39.24M | +25.6% |
| Capital expenditure | — | — | -$54.00K | -$64.00K | — | — |
| Investing cash flow | $15.76M | $42.40M | $58.94M | $48.19M | $12.77M | -62.8% |
| Financing cash flow | $2.53M | $598.00K | $1.10M | $760.00K | $612.00K | +323.6% |
| Free cash flow | -$35.62M | -$47.85M | -$30.68M | -$22.30M | -$39.29M | +25.6% |
| End cash position | $79.59M | $96.92M | $101.77M | $72.36M | $45.65M | -17.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
5.00
+8.9% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
60
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.76 | -0.73 | +4.1% |
| Mar 2026 | -0.75 | -0.75 | +0.5% |
| Dec 2025 | -0.70 | -0.78 | -11.6% |
| Sep 2025 | -0.78 | -0.63 | +19.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.73 | 8 | $480.29K | -29.7% |
| Next quarter | -0.73 | 8 | $483.57K | -27.6% |
| Current year | -2.90 | 8 | $2.71M | -5.2% |
| Next year | -2.80 | 7 | $1.36M | -49.6% |
Analyst targets & ownership
Mean target$31.14
High target$75.00
Low target$9.00
Implied upside578.49%
Analyst count7
ConsensusNONE
Strong buy / Buy1 / 4
Hold2
Sell / Strong sell0 / 0
Held by insiders14.78%
Held by institutions92.44%
Institutions holding199
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.10
-10.00% from price
SMA 20
5.33
-13.86% from price
SMA 50
6.19
-25.82% from price
SMA 100
6.71
-31.59% from price
SMA 200
11.59
-60.38% from price
EMA 12
5.13
-10.60% from price
EMA 26
5.53
-16.93% from price
EMA 50
6.03
-23.88% from price
RSI (14)
25.8
Oversold
MACD (12,26,9)
-0.39
Hist -0.02
ATR (14)
0.30
6.48% of price
Realised vol 30D
50.2%
Annualised
Bollinger upper
5.97
20, 2σ
Bollinger lower
4.69
20, 2σ
50 / 200 cross
Death
6.19 vs 11.59
Trend bias
Below 200
-60.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.09
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
50.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-85.9%
Peak to trough
Max drawdown 5Y
-85.9%
Peak to trough
ATR 14
0.30
6.48% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
4.49M
Prior 4.02M
Change vs prior
+11.8%
Shorts adding
% of float
12.60%
Elevated
% of shares out
8.20%
Against total outstanding
Days to cover
7.4
Crowded exit
Float
42.81M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Aug 12, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jun 12, 26 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Jun 3, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| May 14, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 27, 26 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Dec 18, 25 | Mizuho | INITIATED | — | Outperform |
| Dec 2, 25 | LifeSci Capital | INITIATED | — | Outperform |
| Nov 18, 25 | Evercore ISI Group | INITIATED | — | Outperform |
| Oct 14, 25 | Truist Securities | INITIATED | — | Buy |
| Nov 5, 24 | JP Morgan | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-01
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEFA14A · 2026-04-16
Corporate Changes & Voting Matters
8-K · 2026-03-26
Corporate Changes & Voting Matters
8-K · 2026-02-11
Corporate Changes & Voting Matters
8-K · 2025-11-05
Headlines
Top Premarket Gainers
MT Newswires · 29d ago
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
GlobeNewswire · 29d ago
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
MT Newswires · 36d ago
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 57d ago
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
GlobeNewswire · 57d ago
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 85d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.